1. Home
  2. MCY vs RYTM Comparison

MCY vs RYTM Comparison

Compare MCY & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mercury General Corporation

MCY

Mercury General Corporation

N/A

Current Price

$104.15

Market Cap

5.5B

Sector

Finance

ML Signal

N/A

Logo Rhythm Pharmaceuticals Inc.

RYTM

Rhythm Pharmaceuticals Inc.

N/A

Current Price

$94.30

Market Cap

6.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MCY
RYTM
Founded
1961
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.5B
6.3B
IPO Year
1995
2017

Fundamental Metrics

Financial Performance
Metric
MCY
RYTM
Price
$104.15
$94.30
Analyst Decision
Strong Buy
Analyst Count
0
19
Target Price
N/A
★ $140.53
AVG Volume (30 Days)
220.8K
★ 613.6K
Earning Date
11-03-2026
11-03-2026
Dividend Yield
★ 1.24%
N/A
EPS Growth
15.62
★ 28.34
EPS
★ 8.20
N/A
Revenue
★ $5,992,468,000.00
N/A
Revenue This Year
$4.51
$66.14
Revenue Next Year
$6.66
$79.25
P/E Ratio
$12.50
★ N/A
Revenue Growth
★ 9.44
N/A
52 Week Low
$76.00
$74.50
52 Week High
$113.06
$122.20

Technical Indicators

Market Signals
Indicator
MCY
RYTM
Relative Strength Index (RSI) 54.52 55.32
Support Level $100.24 $82.92
Resistance Level $107.88 $94.94
Average True Range (ATR) 2.33 2.93
MACD -0.03 1.12
Stochastic Oscillator 56.72 90.26

Price Performance

Historical Comparison
MCY
RYTM

About MCY Mercury General Corporation

Mercury General Corp is an insurance holding company. It is engaged in writing personal automobile insurance and provides related property and casualty insurance products. The company offers the following types of automobile coverage: collision, property damage, bodily injury (BI), comprehensive, personal injury protection (PIP), underinsured and uninsured motorist, and other hazards. Additionally, it offers the following types of homeowners coverage: dwelling, liability, personal property, and other coverages. The company has one reportable business segment, the Property and Casualty business segment.

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.

Share on Social Networks: